1. Home
  2. NEXR vs ARTL Comparison

NEXR vs ARTL Comparison

Compare NEXR & ARTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

NEXR

Nexera Technologies Ltd Ordinary Shares

N/A

Current Price

$0.47

Market Cap

4.2M

ML Signal

N/A

Logo Artelo Biosciences Inc.

ARTL

Artelo Biosciences Inc.

HOLD

Current Price

$1.10

Market Cap

4.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NEXR
ARTL
Founded
N/A
2011
Country
Israel
United States
Employees
38
7
Industry
Other Specialty Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.2M
4.3M
IPO Year
2022
N/A

Fundamental Metrics

Financial Performance
Metric
NEXR
ARTL
Price
$0.47
$1.10
Analyst Decision
Hold
Analyst Count
0
2
Target Price
N/A
N/A
AVG Volume (30 Days)
18.1M
177.5K
Earning Date
N/A
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.50
$0.96
52 Week High
$1.28
$23.85

Technical Indicators

Market Signals
Indicator
NEXR
ARTL
Relative Strength Index (RSI) 43.10 35.13
Support Level N/A $1.08
Resistance Level $1.28 $1.87
Average True Range (ATR) 0.14 0.08
MACD -0.03 0.04
Stochastic Oscillator 3.33 38.92

Price Performance

Historical Comparison
NEXR
ARTL

About NEXR Nexera Technologies Ltd Ordinary Shares

Nexera Technologies Ltd focuses on homeland security technologies, artificial intelligence-driven solutions, and detection systems through its subsidiaries and strategic collaborations. The company collaborates with technology partners to distribute and promote new systems such as 3D imaging and electromagnetic threat detection tools, autonomous security technologies, and multi-layered security ecosystems for critical infrastructure and high-traffic venues.

About ARTL Artelo Biosciences Inc.

Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.

Share on Social Networks: